Serotonin and Norepinephrine Reuptake Inhibitor Drug Class List

Drugs in Drug Class: Serotonin and Norepinephrine Reuptake Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heritage	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	078554-004	Jan 9, 2009	AB	RX	No	No
Annora Pharma	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	212277-002	Jul 8, 2019	AB	RX	No	No
Yichang Humanwell	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	214654-002	Aug 6, 2021	AB	RX	No	No
Amneal Pharms	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	079098-003	May 11, 2010		DISCN	No	No
Alembic Pharms Ltd	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	078932-001	Dec 14, 2010	AB	RX	No	No
Aurobindo Pharma	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	090555-003	Apr 7, 2010	AB	RX	No	No
Yaopharma Co Ltd	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET;ORAL	202036-005	May 28, 2015	AB	RX	No	No

Serotonin and Norepinephrine Reuptake Inhibitor Market Analysis and Financial Projection

The global Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) market is experiencing steady growth driven by rising mental health needs, while facing challenges from patent expirations and evolving innovation strategies. Here's a detailed analysis of the market dynamics and patent landscape:

---

Market Dynamics

Growth Drivers

• Mental Health Prevalence: Depression affects 3.8% of the global population (280 million people), with higher rates in women and those over 60[1][6]. Anxiety and chronic pain conditions further boost SNRI demand.
• Aging Populations: Geriatric populations are more susceptible to neurological disorders, driving SNRI adoption[1][9].
• Treatment Advancements: SNRIs are preferred over older antidepressants (e.g., tricyclics) due to fewer side effects and broader efficacy for depression, anxiety, and chronic pain[5][12]. For example, SNRIs accounted for 48.1% of the antidepressant market in 2025[9].

Market Performance

• The SNRI market was valued at $6.29 billion in 2023, with a projected CAGR of 3.8–4.2% through 2030[1][3]. SNRIs dominate the depression drugs market, expected to double sales by 2031[6].
• Regional Trends:
  • North America leads due to high adoption rates and favorable reimbursement policies[1].
  • Asia-Pacific is the fastest-growing region, fueled by generic drug launches and improving healthcare infrastructure[1][7].

Challenges

• Side Effects: Hypertension, constipation, and cardiovascular risks limit use in some patients[10][12].
• Cost and Efficacy: High treatment costs and variable patient responses restrain market growth[1].

---

Patent Landscape

Key Innovations and Expirations

• Expiring Patents: Major SNRI drugs face patent cliffs in 2025–2026, including Regeneron’s Eylea and Bayer’s Xarelto[13][14]. This will accelerate generic competition, impacting revenue for originators.
• New Developments:
  • Pipeline Drugs: Companies like Luye Pharma are advancing novel SNRI candidates (e.g., LY03005) with patents granted in the U.S., Europe, and Asia[17].
  • Improved Formulations: Patents such as US20070015791A1 cover SNRIs with reduced norepinephrine activity to minimize side effects like hypertension[10].
  • Combination Therapies: Patent EP1541197B1 describes combinations of SNRIs with pipamperone for mood disorders[2].

Strategic Trends

• Personalized Medicine: Pharmacogenomics is enabling tailored SNRI treatments based on genetic profiles[8].
• Digital Health Integration: Companies are merging SNRIs with telehealth platforms to enhance patient adherence[8].
• Emerging Markets: Pharma firms are targeting Asia-Pacific and Latin America with affordable generics and localized partnerships[8][17].

---

Competitive Landscape

• Key Players: Leading companies are diversifying portfolios with next-gen SNRIs and biosimilars. For example, Tonix Pharmaceuticals secured a patent for intranasal SNRI delivery (expiring in 2030)[15].
• R&D Focus: Innovations aim to improve safety profiles, such as compounds with low norepinephrine inhibition to reduce cardiovascular risks[10].

---

Key Takeaways

• The SNRI market is expanding due to unmet mental health needs but faces headwinds from generics and side-effect concerns.
• Patent expirations in 2025–2030 will reshape competition, while R&D focuses on safer, targeted therapies.
• Growth opportunities lie in digital health integration and untapped markets in Asia-Pacific and Latin America.

"The introduction of SNRIs with improved safety profiles and rapid onset could redefine treatment paradigms for depression and chronic pain." – Industry Analyst[8][10]

References

1. https://www.coherentmarketinsights.com/market-insight/serotonin-norepinephrine-inhibitor-market-5718
2. https://patents.google.com/patent/EP1541197B1/en
3. https://www.coherentmarketinsights.com/blog/insights/leading-companies-serotonin-norepinephrine-inhibitor-industry-2091
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC2719790/
5. https://www.imarcgroup.com/depression-drugs-market
6. https://www.factmr.com/report/3215/depression-drugs-market
7. https://psychedelicalpha.com/news/p%CE%B1-psychedelic-patent-analysis-october-2023
8. https://sites.google.com/view/precise-research/drive-your-success/serotonin-and-norepinephrine-reuptake-inhibitor-market-by-application
9. https://www.coherentmarketinsights.com/industry-reports/antidepressant-market
10. https://patents.google.com/patent/US20070015791A1/en
11. https://www.lohocla.com/research/patents/
12. https://market.us/report/antidepressants-drugs-market/
13. https://www.fiercepharma.com/pharma/closer-look-pharmas-top-patent-losses-2025
14. https://www.proclinical.com/blogs/2024-2/top-10-drugs-with-patents-due-to-expire-in-the-next-5-years
15. https://www.biospace.com/press-releases/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-by-the-united-states-patent-and-trademark-office-covering-the-intranasal-delivery-of-fda-approved-tosymra-to-treat-migraines
16. https://www.lexisnexisip.com/resources/patent-landscape-analysis/
17. https://www.luye.cn/lvye_en/view.php?id=1954